THIS report is concerned with the experiences of my colleagues and me during the past three years in the use of testosterone in the treatment of 18 patients with far advanced carcinoma of the breast. From these experiences we have drawn certain conclusions as to its place in the treatment of this type of malignant growth.
Although carcinoma of the breast averages about 20 to 25 per cent of all cancer in women and in them is the commonest form of the disease,1 it is less rapidly fatal than most neoplasms of this histologic type.
The life expectancy of untreated patients has been repeatedly computed and averages about three and a third years. For this reason the custom of speaking of two, three or five year survivals in measuring the efficacy of any given form of treatment for cancer of the breast is of doubtful value. Cadela has
KING WG. TREATMENT OF FAR ADVANCED CARCINOMA OF THE BREAST: Present Status of Testosterone Therapy. Arch Surg. 1950;61(4):630–653. doi:10.1001/archsurg.1950.01250020636004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: